Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Solid Tumors 5Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Rectal Neoplasms 2Colonic Neoplasms 2Solid Tumor 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma 1

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡